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Previous work suggest a positive skeletal muscle effect of hormone replacement therapy
(HRT) on skeletal muscle characteristics This study aimed to quantify any continued positive
effect of HRT even after a sustained hiatus in treatment, controlling for two key muscle mod-
ulation hormones: Estradiol (E2) and Tri-iodo-thyronine (T3).
Method and findings
In 61 untrained women (18-78yrs) stratified as pre-menopausal, post-menopausal without
(No_HRT) and post-menopausal with (Used_HRT) HRT history, body composition, physical
activity, serum E2 and T3 were assessed by dual energy x-ray absorptiometry, Baecke
questionnaire and ELISA. Gastrocnemius medialis (GM) and tibialis anterior (TA) electro-
myographic profiles (mean power frequency (mPowerF)), isometric plantar-flexion (PF) and
dorsi-flexion (DF) maximum voluntary contraction (MVC), rate of torque development
(RTD), isokinetic MVC and muscle volume, were assessed using surface electromyogra-
phy, dynamometry and ultrasonography. Muscle quality was quantified as MVC per unit
muscle size. E2 and E2:T3 ratio were significantly lower in postmenopausal participants,
and were positively correlated with RTD even after controlling for adiposity and/or age. Pre-
menopausal females had greater MVC in 8/8 PF and 2/5 DF (23.7–98.1%; P<0.001–0.049)
strength measures compared to No_HRT, but only 6/8 PF (17.4–42.3%; P<0.001–0.046)
strength measures compared to Used_HRT. Notably, Used_HRT had significant higher
MVC in 7 PF MVC (30.0%-37.7%; P = 0.006–0.031) measures than No_HRT, while pre-
menopausal and Used_HRT had similar uncorrected muscle size or quality. In addition, this
cross-sectional data suggest an annual reduction in GM muscle volume corrected for intra-
muscular fat by 1.3% in No_HRT and only 0.5% in Used_HRT.
PLOS ONE
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Conclusion
Even years after cessation of the therapy, a history of HRT is positively associated with
negating the expected post-menopausal drop in muscle quantity and quality. Whilst mPo-
werF did not differ between groups, our work highlights positive associations between RTD
against E2 and E2:T3. Notwithstanding our study limitation of single time point for blood
sampling, our work is the first to illustrate an HRT attenuation of ageing-related decline in
RTD. We infer from these data that high E2, even in the absence of high T3, may help main-
tain muscle contractile speed and quality. Thus our work is the first to points to markedly
larger physiological reserves in women with a past history of HRT.
Introduction
Animal and human models have long shown that ageing is associated with a substantial slow-
ing in contraction duration and half-relaxation time of skeletal muscle fibers [1]. These func-
tional changes in the twitch parameters are accompanied with an increase in the relative
proportion of slow type I fibers compared with fast type II fibers [1–5]. In fact, age-related
slowing of contractile properties may well be attributable to a preferential atrophy of fast fibers,
resulting in an increased areal percentage of type I fibers [6], and a slowing of type I [7] and
type IIa fibers [8]. What is also widely known is that there are over 3000 genes that are differen-
tially expressed in males vs female skeletal muscle [9]. It is also clear that the sex-based differ-
ences are regulated by a number of hormones, especially thyroid hormone and gonadal
hormones (for a review please read [10].
In much the same way as ageing affects estrogen levels, exercise training is also an impor-
tant modulator of estrogen levels, thus establishing the efficacy of estrogen in muscle hypertro-
phy. In previous work, two key observations were made: (1) anabolic androstenedione-doped
human participants exhibit increased testosterone and subsequently estrogen levels, (2) ana-
bolic androstenedione-doped human participants show significant increases in lean tissue
content [11]. This in itself is not a surprise since the aromatization of testosterone to estrogen,
is necessary for the muscle hypertrophic effect of the former to become possible [12]. In fact,
work using amenorrheic [13] or post-menopausal females [14], is especially relevant here in
demonstrating the theorem that estrogen is important for skeletal muscle structure and func-
tion. Indeed a substantial body of work shows a link between lowered circulating estrogen lev-
els, and muscle atrophy as well as poor physical performance [15, 16]. Also of note, is the
previous research showing that obesity is one of the key factors linked to an overall increase in
concentrations of free circulating biologically active estradiol (17β-estradiol). In fact, such
research shows that in overweight/obese women a 16–24% higher circulating level of estradiol
is observed compared to age-matched counterparts, even after adjustment for covariates [17].
Also of relevance, is the observation that obesity is associated with a higher proportion of gly-
colytic type IIB fibers (for a review, see [18]). Thus, it appears important to take body composi-
tion (% body fat and % lean tissue) into account when considering the impact of estrogen in
modulating the rate of age-related loss of skeletal muscle mass and strength in older women.
As mentioned above, estrogen and thyroid are two key hormones in relation to the origin
of sex-based differences in skeletal muscle phenotype. Thyroid hormone, like estrogen, is a
pluripotent hormone and it exhibits dual effects in many systems. The link between thyroid
hormones and muscle fiber type is an often overlooked relationship especially in in vivo stud-
ies. Notwithstanding this omission, the body of work suggesting that thyroid levels ought to be
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considered in any study pertaining to comment on muscle fiber phenotype is substantive. A
case in point, hypothyroidism is a clinical condition in which up to 80% of patients experience
one or another form of myopathy [19]. Moreover, as far back as the mid-1970s, it was first
reported that in humans, hypothyroid myopathy is linked to biopsy-assessed type II fiber type
atrophy in the vastus lateralis muscle [20]. Corroborating a causal link between fiber type and
thyroid hormones, and adding an element of gender specificity to this relationship, previous
research directly supplemented male and female rats with tri-iodo-thyronine (T3), and quanti-
fied the velocity of muscle contractions as well as myosin heavy chain composition. The
researchers report that whilst the T3 treatment increased the velocity of contraction as well as
upregulated fast myosin heavy chain (irrespective of age), this effect was not seen in the male
models, suggesting an interaction between estrogen and thyroid in the regulation of fiber type
composition [21]. Others have also observed a gonadal-hormones-linked sensitivity to T3
effects, at least in animal models [22]. As such it is pertinent that in an effort to individualize
tomorrow’s clinical interventions, an understanding of how various factors interact is clarified.
A group known to experience drastic deleterious changes in physical function, hence worthy
of further study, is post-menopausal women.
Despite this existing body of work, there is no current study clarifying, using non-invasive
or otherwise methods, the degree to which gonadal and thyroid hormones influence skeletal
muscle phenotype in the postmenopausal female. The objective of the current cross-sectional
study was to determine any covariation between thyroid hormone (Tri-iodo-thyronine (T3))
and Estradiol (E2) levels and in vivo muscle size, strength, quality and indirect indices of fiber
type composition in pre vs. post-menopausal women. A secondary objective was to determine
the degree to which HRT history preserves post-menopausal muscle function. Therefore, it
was hypothesized that: (1) Lower levels of E2 (and/or no HRT history) is linked to decreased
muscle function (decreased isometric MVC, isokinetic strength and muscle quality), (2) Age-
ing is associated with perceptible decrements in T3 levels thereby modulating muscle activa-
tion profile and hence potentially indicating fiber type percentage shift towards a slow
phenotype (resulting in slower rate of torque development–RTD—and lower Mean Power
Frequency–mPowerF-); (3) estradiol to Tri-iodo-thyronine ratio (i.e. E2:T3) is a useful endo-
crine modulator of skeletal muscle phenotype, (4) high body fat in the post-menopausal status
alters muscle EMG profile and RTD (where both are potential indirect indices of muscle fiber
type- see details in the Methods), likely through decreasing the fast-to-slow transition of fiber
type) in older women.
Materials and methods
Participants
Sixty-one untrained women aged 45 ± 22yrs (range: 18-78yrs) that were considered represen-
tative for the wider population were recruited and categorized by their menopause status and
additionally by HRT use history (only postmenopausal). Participants were recruited using
convenience sampling by word of mouth and presentations at both Manchester Metropolitan
University and the University of the Third Age in Cheshire (UK). All studies took place at the
laboratories of the Research Centre for Musculoskeletal Science and Sports Medicine (previ-
ously Health Exercise & Active Living) at the Cheshire campus of Manchester Metropolitan
University. Prior to the undertaking of assessments, a general health questionnaire and screen-
ing of participants’ level of physical activity was ascertained using the Baecke physical activity
questionnaire that is composed of 3 sections detailing, work, structured sport and leisure phys-
ical activity [23]. During this process, participants’ menopausal age, use of HRT and duration
of treatment, use of the contraceptive pill and years of use, along with any current medications
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that may affect thyroid T3 levels were noted. Participants’ were excluded if their current level
of exercise exceeded 2 hours of structured moderate/vigorous physical activity per week, if
they had substantially changed their habitual physical activity levels and diet in the past 12
months and were taking any medication that may affect maximum effort during testing. Prior
to the commencement of the study, participants gave their written informed consent and all
the procedures in this study had approval from the local Manchester Metropolitan University
ethics committee (Ethics Committee Reference Number: 09.03.11 (ii)).
Protocol
On the first visit to the laboratory, participants completed the informed consent form and
were screened for potential participation using their answers in the general health and physical
activity questionnaire. Following acceptance onto the study, participants then undertook a
7-minute dual energy x-ray absorptiometry (DEXA) scan followed by a fasted blood sample
and familiarization of the strength testing procedure. On their second and final visit to the lab-
oratory, participants completed the full strength protocol assessing maximal voluntary con-
traction (MVC), rate of torque development, both muscle activation and co-activation of the
gastrocnemius medialis (GM) and tibialis anterior (TA) muscles using surface electromyogra-
phy (sEMG), and finally GM muscle volume.
Measurement of body composition
DEXA (Hologic Discovery: Vertec Scientific Ltd, Reading, UK) was used to ascertain partici-
pants’ body composition following an overnight 12-hour fast. A detailed description of the
7-minute standardized scanning procedure (whole body, EF 8.4 lSv) is reported previously
[24]. Scan results were calculated using the Hologic APEX software (version 3.3) and presented
in terms of whole body lean mass and fat mass, with the same researcher completing scanning
and analysis. Primarily DEXA was utilized to quantify total lean and fat mass (along with body
fat percentage) for general descriptive characteristics in order to observe how well the sample
was matched owing to the influence body composition has upon skeletal muscle characteristics
[24]. Secondly, total fat and body fat percentage were utilized as a covariate in correlations due
to its impact on estrogen levels [17].
Serum collection
Following the completion of the DEXA scan, 61 participants provided a 10mL fasted (12
hours) blood sample between 8am and 9am, having not performed strenuous exercise for 48
hours prior. Blood was collected in anticoagulant-free vacutainers (BD Vacutainer Systems,
Plymouth, UK) and rested on crushed ice for 10–15 minutes. Samples were then placed into a
refrigerated centrifuge at 4˚C (IEC CL31R, Thermo Scientific, Massachusetts, United States)
for 10 minutes at 2700� g after which serum was extracted and stored in 2mL aliquots at
−20˚C until subsequent analysis.
Muscle strength
Following familiarization on the first visit to the laboratory to the strength testing procedure,
plantar flexion (PF) and dorsiflexion (DF) MVC torque was assessed in the participants’ self-
selected dominant limb using an isokinetic dynamometer (Cybex Norm, Cybex International,
New York, NY, USA) at three different ankle angles (10˚, 0˚/neutral angle and -5˚) and one
isokinetic speed (60˚�sec-1). Participants were seated in a supine position with a hip angle of
85˚ and their self-selected dominant leg fully extended. The dominant foot was secured to the
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footplate of the dynamometer using fixed unyielding straps, whilst ensuring the lateral malleo-
lus was aligned with the center of rotation of the dynamometer. Participants were additionally
strapped at the hip, distal thigh and chest with fixed unyielding straps to minimize synergistic
movement that may unintentionally alter force production from the desired muscle group.
Prior to undertaking any MVCs, the participants completed a series of 4–8 warm-up PF and
DF contractions at 50% of their self-perceived maximal effort. Participants subsequently per-
formed four isometric MVC first with PF (×2) and then DF (×2) at each of the three ankle
angles and one isokinetic speed, with 2 minutes of rest between contractions. The order of the
contractions was randomized for each participant, with the first angle being repeated at the
end to ensure adequate warm-up and to diminish any learning effect and/or development of
fatigue between contractions. MVCs were repeated if there was >10% difference between
MVCs to ensure participants’ true MVC was obtained for each angle. The highest recorded PF
and DF MVCs were used for subsequent analysis. Verbal encouragement and on-screen bio-
feedback were provided during each effort.
EMG and RTD as potential indirect fiber type indices
In view of such potentially impactful research on post-menopausal women, the issue of meth-
odology may sometimes be limiting, especially with invasive laboratory protocols. The major-
ity of in vivo human studies commenting on muscle fiber composition of muscles have utilized
biopsy material to determine myosin heavy chain composition (through myosin adenosine tri-
phosphatase/mATPase enzyme activity) and hence classify a muscle as fast, intermediate or
slow. By its nature however, this methodology is invasive. Non-invasive ways to assess fiber
type composition have been developed, such as tensiomyography [25] and electromyography/
EMG [26]. When action potentials travel along the sarcolemma of muscle fibers to simulate
these into a contraction, they create a myoelectric signal (intensity and pattern) the sum of
which is captivated using either intramuscular-iEMG or surface-sEMG. It is understood that
sEMG power spectrum shifts towards lower frequencies during isometric contractions [27].
This shift is similar to observations using iEMG, as such they confirm the validity of sEMG
data as representative of muscle activation. Using isolated rat muscles for instance, it has sys-
tematically been demonstrated that muscles with a high proportion of fast glycolytic or with
fast oxidative fibers have a higher sEMG signal as quantified by the mean power frequency
(mPowerF) [26]. This observation demonstrates that sEMG, especially that recorded during
contractions, can reliably and singularly be linked to the muscle’s fiber type composition (as
well as muscle fiber cross-sectional area- aCSA) [26]. The potency of the sEMG signal to pro-
vide information on muscle fiber type composition is also supported by authors who propose
and/or demonstrate that free-living EMG data are to be incorporated towards the development
of externally valid mathematical models of intrinsic skeletal muscle properties [28, 29]. More
recently thus, human work has also been conducted which corroborates the fact that the elec-
trical signal of muscle is a strong signature for its fiber type composition [26, 30–32].
RTD development was calculated using the highest MVC at 0˚, then utilizing the slope of
the torque curve from the onset of contraction at intervals of 0-50ms, 0-100ms, 0-150ms and
0-200ms.
sEMG (using pre-gelled unipolar Ag-AgCl electrodes (Medicost, Denmark)) was used to
assess muscle activation from the mean power frequency (mPowerF) of the GM and TA and
additionally muscle co-contraction of the TA during PF MVC at the three designated angles.
Two sEMG electrodes (skin contact size 30 mm×22 mm) were placed proximally at one third
of the GM and TA muscle length, mid muscle belly, with a 1–2-mm gap between each elec-
trode. Two reference electrodes (Medicost, Denmark) were placed on the head of the fibula
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and medial tibial condyle. Raw EMG was then recorded at 2,000 Hz, with the band pass filter
set at 10–500 Hz and notch at 50 Hz. Calculation of co-activation was then utilized to quantify
participants’ true PF MVC accounting for co-contraction.
Muscle activation, co-activation and net MVC
Calculation of muscle co-activation (%) at 10˚, 0˚ and -5˚ ankle angle was conducted utilizing
the raw EMG signal (computed as root mean square (RMS) 500 ms either side of the instanta-
neous peak torque) of the TA during PF MVC divided by sEMG during DF MVC. Co-contrac-
tion torque was the product of percent co-contraction and maximal DF torque, assuming that
the DF EMG/torque relationship is linear as demonstrated by previous authors [33]. Hence,
net PF MVC torque was calculated as the sum of observed maximal PF torque and co-contrac-
tion torque.
Net MVC = PF MVC torque + DF co-contraction torque
mPowerF of the raw sEMG signal using Fast Fourier Transform (AcqKnowledge software
(version 4.2; Biopac-Systems, Goleta, CA) was obtained over 1 second prior to PF and DF
MVC, during MVC and post MVC at 0˚ (neutral) ankle angle. Within the study, based on the
rationale detailed at the beginning of this section, a higher mPowerF was proposed to poten-
tially be indicative of a greater proportion of type II fiber composition within the working
muscle.
Gastrocnemius medialis muscle volume
Calculation of GM muscle volume was undertaken through the assembly of anatomical cross-
sectional areas at 25, 50 and 75% of resting GM length of participants’ dominant leg using B-
mode ultrasonography (AU5 Harmonic, Esaote Biomedica). Detailed description of the meth-
odology is reported in [34]. All scans and measurements were undertaken by the same investi-
gator. The assessment of GM muscle volume utilized the truncated cone method which has
previously been shown to have high reliability [34], and strong agreement with MRI-obtained
values [35]. Correction for intramuscular adipose tissue (IMAT) within the GM Muscle Vol-
ume was undertaken using data reported by Csapo et al. [36], where young women were
shown to have 4.6%, whilst older women exhibited 8.1% IMAT. Thus:
Muscle Quality (uncorrected) = (peak PF MVC torque + DF co-contraction torque)�Muscle
Volume (uncorrected for IMAT)
Muscle Quality (corrected) = (peak PF MVC torque + DF co-contraction torque)�Muscle
Volume (corrected for IMAT)
Where peak torque is the highest recorded MVC over 10˚, 0˚ and -5˚, corrected for co-con-
traction, and divided by muscle volume, the latter corrected for standard IMAT value. For
uncorrected muscle, the same calculation applied though it utilized the raw (i.e. uncorrected)
peak torque data, and the raw muscle volume data.
Serum estradiol and tri-iodo-thyronine concentration
Estradiol (R&D Systems, Minneapolis, USA) and T3 (Abbexa Ltd., Cambridge UK) serum
concentrations were measured using enzyme-linked immunosorbent assay (ELISA), following
the manufacturer’s instructions. Estradiol assay sensitivity reported by the manufacturer is
12.1 pg/mL, range 12.3–3,000 pg/mL, Minimum Detectable Dose 4.84 pg/ml, with an intra-
assay precision of 5.97% coefficient of variation (CV) and an inter-assay precision of 7.13%. T3
assay sensitivity reported by the manufacturer is < 35 pg/mL, range 78 pg/mL—5000 pg/mL,
with an intra-assay precision <7.2% CV and an inter-assay precision at<10.1% CV. Serum
samples were run in duplicate and in our hands CVs of 5.7% for E2 and 4.1% for T3 were
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attained. The mean of each sample was taken as the hormone concentration. Samples were
then analyzed using an EL808™ Absorbance Microplate Reader (BioTek, Vermont, US) and
software Gen5 (version 1.11; BioTek, Vermont, US). There was insufficient serum volume for
13 participants when undertaking analysis of T3 resulting in a sample size of 48 for the T3
data.
Statistical analyses
Statistical analyses were carried out using SPSS (Version 22, SPSS Inc., Chicago, IL, USA).
Parametricity was determined through both the Kolmogorov-Smirnov test (Whole sample)
and Shapiro–Wilk test (premenopausal, postmenopausal (No_HRT) postmenopausal
(Used_HRT)) testing normality of the data. Assessment of equality of variances between
groups was conducted by the Levene’s test. If parametric assumptions were met, between
group differences were examined by a one-factor ANOVA (pre-menopause, postmenopausal
No_HRT and Used_HRT) with post-hoc pairwise comparisons conducted using the Bonfer-
roni correction. However, if parametric assumptions were breached, between group differ-
ences were examined by a Kruskal-Wallis non-parametric ANOVA (pre-menopause,
postmenopausal No_HRT and Used_HRT) with post-hoc pairwise comparisons being exam-
ined by Mann-Whitney U test. Pearson (or Spearman rank order for non-parametric data
sets) correlations were used to define any associations between skeletal muscle functional
properties vs. E2, T3 levels and E2:T3 ratio. Co-variates were considered total fat mass, BMI,
total body mass or age with the confounding variable status ascertained through correlation
analysis against the outcome measure of interest. Partial correlations, were carried out to con-
trol for body composition or age, to allow ‘hormones only effects’ to be discerned. Data are
reported as Mean±SD and statistical significance was accepted when P�0.05. Study power (β)
and effect size (p
2) are also reported. Statistical trends indicate 0.05>p<0.1.
Results
Descriptive characteristics of participants
Table 1 displays participants’ characteristics, segregated by participants’ estrogen background
(pre vs post-menopause phase and HRT history). As expected, a Kruskal Wallis non-paramet-
ric ANOVA revealed a significant difference in age between pre vs post-menopausal women
(P<0.001), but none between postmenopausal No-HRT vs Used_HRT (i.e. post-menopausal
women were older than their pre-menopausal counterparts, but the two post-menopausal
groups were of similar age). Another difference was where pre-menopausal women had a
lower body fat percentage than both post-menopausal groups, whilst the two post-menopausal
groups did not differ (P<0.001). With total fat mass, on the other hand, pre-menopausal
women only exhibited a significant lower value compared to the Used_HRT (P = 0.039); whilst
again, the two post-menopausal groups did not significant differ from one another. In other
parameters, the three groups (pre-menopausal, No_HRT and Used_HRT) were well-matched
with no statistical differences in height, body mass, BMI, lean mass, or physical activity scores
(work, sport, leisure and global scores) between the groups (Table 1).
Starting with Estradiol, unsurprisingly a Kruskal Wallis non-parametric ANOVA revealed
a main effect of menopause phase/HRT (P<0.001). Pairwise comparisons revealed pre-meno-
pausal participants to have 293% (P<0.001) and 315% (P<0.001) greater Estradiol concentra-
tion than their post-menopausal No_HRT and HRT_user counterparts (Table 2), with no
difference in Estradiol between the two post-menopausal subsets (p>0.05).
Notably, there was no main effect of estrogen status on T3 levels as noted in Table 2. Still,
there was a trend for pre-menopausal participants to have -14% (P<0.1) lower T3 than
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Used_HRT, and conversely 17% (P<0.1) greater T3 than No_HRT, and for Used_HRT to
have 35% higher T3 than the No_HRT group (Table 2).
The large Estradiol group differences were mirrored by E2:T3 ratio as a one factor ANOVA
revealed a main effect of menopause phase/HRT use (P = 0.001; p2 = 0.654; β = 1.000). Pairwise
comparisons revealed pre-menopausal participants to have 237% (P<0.001) and 334%
(P<0.046) greater E2:T3 ratio than both their post-menopausal No_HRT and HRT_user
counterparts (Table 2).
Co-variates identification
Table 3 illustrates associations between measures of body composition and age against a series
of skeletal muscle structural and functional characteristics and hormone levels to identify
Table 1. Descriptive participant and hormone characteristics grouped by menopause phase and use of hormone replacement therapy (HRT).
Post-Menopausal
Pre-Menopausal (n = 33) No HRT (n = 12) Used HRT (n = 16)
Participant Characteristics
Age (years) 27 ± 11 a 69 ± 6 b 65 ± 7 b
Height (cm) 166 ± 8 a 161 ± 4 a 161 ± 5 a
Body Mass (kg) 70 ± 21 a 71 ± 12 a 72 ± 12 a
BMI (kg/m2) 25.6 ± 7.3 a 27.4 ± 4.6 a 27.6 ± 4.4 a
Body Fat (%) 33.8 ± 5.2 a 42.1 ± 4.7 b 42.3 ± 5.1. b
Fat Mass (kg) 24.7 ± 13.7 a 29.5 ± 7.7 ab 29.9 ± 8.2 b
Lean Mass (kg) 41.8 ± 8.0 a 37.6 ± 4.9 a 37.5 ± 4.3 a
ASM (kg) 17.0 ± 3.4 a 16.1 ± 3.2 a 17.8 ± 4.1 a
ASM/Height2 (kg/m2) 6.2 ± 1.1 a 6.2 ± 1.1 a 6.7 ± 1.3 a
No of Contractive Pill users 16/33 5/12 12/16
Average years of Pill use 2.5 ± 3.9 a 5.4 ± 8.3 ab 7.1 ± 6.8 b
Menopause Age (yrs) N/A 51 ± 4 a 47 ± 6 a
Average years of HRT use N/A N/A 7.8 ± 5.2
Average years since HRT use N/A N/A 10.6 ± 8.9
Physical Activity Scores
Work 2.38 (0.69) a 2.44 (0.34) a 2.69 (0.34) a
Sport 2.75 (1.00) a 2.50 (1.50) a 2.25 (0.25) a
Leisure 2.75 (0.88) a 3.25 (0.94) a 2.75 (0.75) a
Global 7.75 (1.50) a 8.38 (0.97) a 7.50 (0.84) a
Participant Characteristics values are means ± SDs. Physical Activity Score values are median (interquartile range). Labelled menopause/HRT status means in a row
without a common letter differ, P < 0.05. ASM, Appendicular Skeletal Muscle Mass
https://doi.org/10.1371/journal.pone.0250813.t001
Table 2. Serum estradiol and tri-iodo-thyronine concentrations classified by menopause phase and use of hormone replacement therapy (HRT).
Post-Menopausal
Pre-Menopausal (n = 33) No HRT (n = 12) Used HRT (n = 16)
Hormone Levels
Estradiol (E2) pg/ml 191 ± 31 a 49 ± 13 b 46 ± 8 b
Tri-iodo-thyronine (T3) ng/dl 157 ± 92 a 135 ± 53 a 182 ± 129 a
E2/T3 ratio 1.42 ± 0.49 a 0.42 ± 0.18 b 0.33 ± 0.14 b
Values are means ± SDs. Labelled menopause/HRT status means in a row without a common letter differ, P < 0.05.
https://doi.org/10.1371/journal.pone.0250813.t002
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potential co-variates. A spearman rho correlation revealed BMI to be positively correlated with
isokinetic DF MVC (rho = 0.29; P = 0.021) and peak DF MVC (rho = 0.29; P = 0.024), but neg-
atively with muscle quality corrected (rho = -0.36; P = 0.008). Total fat mass was positively cor-
related with isokinetic DF MVC (r = 0.26; P = 0.044), peak isometric DF MVC (rho = 0.30;
P = 0.019) and PF net MVC 0˚ (r = 0.27; P = 0.036), but negatively with muscle quality cor-
rected (rho = -0.36; P = 0.008) and E2:T3 ratio (rho = -0.33; P = 0.024). Body fat percentage
was negatively correlated with corrected muscle quality (rho = -0.39; P = 0.003), Estradiol (rho
= -0.31; P = 0.016) and E2:T3 ratio (rho = -0.55; P<0.001). Age was negatively associated with
Estradiol (rho = -0.773; P<0.001), E2:T3 (rho = -0.630; P<0.001), and lean mass (rho = -0.232;
P = 0.036), but was positively associated with fat mass (rho = 0.336; P = 0.008), percent body
fat (rho = 0.484; P<0.001) and BMI (rho = 0.295; P = 0.021). Data for muscle quality (both
uncorrected and corrected) is shown in Table 3.
Musculoskeletal characteristics
(a) Maximum PF strength. When categorizing the females by menopause phase and
splitting postmenopausal participants by their use of HRT following the menopause, the
results revealed interesting outcomes as noted in Fig 1. A Kruskal Wallis non-parametric
ANOVA revealed a main effect of menopause phase/HRT use on corrected 0˚ MVC
(P<0.001). Pairwise comparisons revealed pre-menopausal participants to have 55%
(P<0.001) and 17% (P = 0.016) greater corrected PF 0˚ MVC than their No_HRT and
Used_HRT. In addition, Used_HRT had 32% (P = 0.006) greater 0˚ MVC than their No_HRT
counterparts (Fig 1A). This pattern was similar for PF 10˚ MVC, as a Kruskal Wallis non-
Table 3. Bivariate and partial (correcting for age) correlations between measures of body composition, skeletal muscle characteristics and hormone levels where co-
variates are identified.
Plantar Flexion Dorsi Flexion
Maximum Voluntary Contraction Muscle Characteristics Hormone Levels
0 deg 10 deg -5 deg Peak
TRQ











BMI (kg/m2) 0.20 0.11 0.17 0.18 0.19 0.25 0.25 0.03 0.29� 0.29� 0.47��� 0.44�� -0.36�� -0.10 -0.05 -0.20
Body Fat (%) -0.10 -0.18 -0.13 -0.12 -0.13 0.09 0.06 -0.02 0.12 0.03 0.25 0.21 -0.48��� -0.31� 0.16 -0.55���
Fat Mass (kg) 0.14 0.06 0.10 0.12 0.12 0.24 0.25 0.04 0.30� 0.26� 0.42�� 0.39�� -0.36�� -0.13 0.05 -0.33�




BMI (kg/m2) 0.41�� 0.33� 0.39�� 0.40�� 0.57��� 0.35�� 0.37�� 0.11 0.39�� 0.48��� 0.52��� 0.51��� -0.20 0.21 0.03 -0.00
Body Fat (%) 0.19 0.10 0.15 0.16 0.33� 0.24 0.24 0.12 0.29� 0.36�� 0.33� 0.31� -0.22 0.12 0.33� -0.33�
Fat Mass (kg) 0.38�� 0.30� 0.34�� 0.36�� 0.51��� 0.35�� 0.38�� 0.14 0.42�� 0.48��� 0.48��� 0.47��� -0.23 0.21 0.15 -0.11




Pearson correlations are highlighted in grey. Abbreviations: deg, degree; E2, Estradiol; isokin, isokinetic; MQ, muscle quality; MV, muscle volume; muscle volume
corrected for intramuscular adipose tissue; MQ (IMAT), muscle quality corrected for intramuscular adipose tissue; Opt, optimum; T3, Tri-iodo-thyronine; TRQ,
torque.
https://doi.org/10.1371/journal.pone.0250813.t003
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parametric ANOVA revealed a main effect of menopause phase/HRT use on corrected 10˚
MVC (P<0.001). Pairwise comparisons revealed pre-menopausal participants to have 58%
(P<0.001) and 21% (P = 0.006) greater corrected PF 10˚ MVC than their No_HRT and
Used_HRT counterparts. In addition, Used_HRT had 30% (P = 0.029) greater PF 10˚ MVC
than their No_HRT counterparts (Fig 1A). At PF -5˚ MVC, a one factor ANOVA revealed a
main effect of menopause phase/HRT use (P<0.001; p
2 = 0.299; β = 0.993). Pairwise compari-
sons revealed pre-menopausal participants to have 60% (P<0.001) greater corrected PF -5˚
MVC than their No_HRT counterparts. In addition, Used_HRT had 38% (P = 0.031) greater
PF -5˚ MVC than their No_HRT counterparts (Fig 1A). This pattern was continued for PF
uncorrected MVC torque as noted in Fig 1. A one factor ANOVA revealed a main effect of
menopause phase/HRT use on isokinetic PF MVC at 60˚�sec-1 (P<0.001; p
2 = 0.435; β =
1.000). Pairwise comparisons revealed pre-menopausal participants to have 97% (P<0.001)
and 42% (P<0.001) greater isokinetic PF MVC than their no_ HRT and Used_HRT counter-
parts. Finally, regarding PF optimal torque MVC, a Kruskal Wallis non-parametric ANOVA
revealed a main effect of menopause phase/HRT use (P<0.001). Pairwise comparisons
revealed pre-menopausal participants to have 58% (P<0.001) and 16% (P = 0.023) greater cor-
rected PF optimal torque than their No_HRT and Used_HRT counterparts, yet Used_HRT
had 35% (P = 0.011) greater optimal torque than their No_HRT (Fig 1A).
(b) Maximum DF strength. With regards to DF, a one factor ANOVA revealed a main
effect of menopause phase/HRT use on isometric DF 10˚ MVC (P = 0.021; p2 = 0.125; β =
0.709). Pairwise comparisons revealed pre-menopausal participants to have 24% (P = 0.021)
greater DF 10˚ MVC than their No_HRT counterparts (Fig 1B). In addition, a one factor
ANOVA revealed a main effect of menopause phase/HRT use on isokinetic DF MVC at 60˚�
sec-1 (P = 0.029; p2 = 0.155; β = 0.665). Pairwise comparisons revealed pre-menopausal partici-
pants to have 44% (P = 0.049) greater isokinetic DF MVC than their post-menopausal
No_HRT counterparts (Fig 1B).
(c) Muscle volume and quality. With regards to GM muscle volume (uncorrected for
IMAT), a Kruskal Wallis non-parametric ANOVA revealed no effect of menopause phase/
HRT use on GM muscle volume (P = 0.154) (see Table 4). This finding was mirrored when
with regards to GM muscle volume corrected for IMAT (P = 0.092). However, a partial corre-
lation between age and GM muscle volume (corrected for IMAT) and controlled for BMI,
revealed a negative association (rho = -0.30; P = 0.031). Interestingly, assuming that the age
Fig 1. Comparison of participants’ plantar flexion (A) and dorsi flexion (B) maximum voluntary contraction at
various isometric ankle angles (0, 10–5 degrees) and one isokinetic speed (60 deg�sec-1) categorized by participants’
menopause phase and use of hormone replacement therapy. Values are means ± SDs. Different from Pre-Menopausal
and Post-Menopausal, � P< 0.05, �� P< 0.01, ��� P< 0.001. Abbreviations: Corr, is MVC Corrected for co-
contraction. Also referred to Net MVC in the text; Deg, Degree; ikin, isokinetic; iso, isometric.
https://doi.org/10.1371/journal.pone.0250813.g001
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related loss of muscle mass at the onset of the menopause (47yrs Used_HRT and 51yrs
No_HRT) is linear, the slope equated to No_HRT participants losing 1.3% of muscle volume
per year in comparison to only 0.5% loss per year in the Used_HRT group.
Interestingly, a one factor ANOVA revealed a main effect of menopause phase/HRT use on
muscle quality when utilizing uncorrected MVC torque (P = 0.013) (See Fig 2A). Pairwise
comparisons revealed pre-menopausal participants to have 38% (P = 0.015) higher muscle
quality than their post-menopausal No_HRT counterparts (Fig 2A), whilst there were no sta-
tistical differences between pre-menopausal and Used_HRT participants. This finding was
mirrored when utilizing MVC torque corrected for co-contraction (P = 0.036; see Fig 2B),
with pairwise comparisons revealing pre-menopausal participants to have 36% (P = 0.032)
higher muscle quality than their post-menopausal No_HRT counterparts (Fig 2A), with again
no statistical differences between pre-menopausal and Used_HRT participants.
(d) Potential indirect muscle fiber type indices: rate of torque development and mean
power frequency). Fig 3 illustrates the effect of menopause phase and use/non-use of HRT
on RTD. A Kruskal Wallis non-parametric ANOVA revealed a main effect of menopause
phase/HRT use on PF RTD 0-50ms (P = 0.003). Pairwise comparisons revealed pre-meno-
pausal participants to have 98% (P = 0.031) and 95% (P = 0.034) greater RTD 0-50ms than
Table 4. Descriptive muscle indices grouped by menopause phase and use of hormone replacement therapy (HRT).
Post-Menopausal
Pre-Menopausal (n = 33) No HRT (n = 12) Used HRT (n = 16)
Muscle Indices
mPowerF Pre PF MVC (Hz) 192 ± 56 186 ± 25 187 ± 27
mPowerF During PF MVC (Hz) 252 ± 22 250 ± 20 233 ± 31
Δ mPowerF PF MVC (Hz) 60 ± 55 65 ± 34 47 ± 35
mPowerF Pre DF MVC (Hz) 289 ± 58 270 ± 49 274 ± 49
mPowerF During DF MVC (Hz) 255 ± 26 246 ± 24 250 ± 16
Δ mPowerF DF MVC (Hz) -34 ± 60 -24 ± 51 -23 ± 50
GM Muscle Volume (cm3) 234 ± 82 185 ± 40 223 ± 65
GM Muscle Volume (Corrected for IMAT) (cm3) 224 ± 78 170 ± 36 205 ± 59
Values are means ± SDs. No differences were observed between menopause phase and use of HRT. Abbreviations: DF, Dorsi Flexion; GM; Gastrocnemius Medialis;
IMAT, Intramuscular Adipose Tissue; mPowerF, mean power frequency; MVC, Maximum Voluntary Contraction; PF, Plantar Flexion
https://doi.org/10.1371/journal.pone.0250813.t004
Fig 2. Comparison of participants’ muscle quality (utilizing uncorrected maximum torque (A) and maximum torque
corrected for co-contraction (B) categorized by participants’ menopause phase and use of hormone replacement
therapy. Values are means ± SDs. Different from Pre-Menopausal and Post-Menopausal, � P< 0.05.
https://doi.org/10.1371/journal.pone.0250813.g002
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their post-menopausal no Used_HRT and No_HRT counterparts (Fig 3). Then for RTD 0-
100ms, A Kruskal Wallis non-parametric ANOVA revealed a main effect of menopause phase/
HRT use (P = 0.018). Pairwise comparisons revealed pre-menopausal participants to have 82%
(P = 0.027) and 75% (P = 0.018) greater RTD 0-100ms than their post-menopausal No_HRT
and HRT_user counterparts (Fig 3A). For RTD 0-150ms, a factor ANOVA revealed a main
effect of menopause phase/HRT use (P = 0.003; p2 = 0.181; β = 0.888). Pairwise comparisons
revealed pre-menopausal participants to have 90% (P = 0.008) and 55% (P = 0.036) greater
RTD 0-150ms than their post-menopausal No_HRT and HRT_user counterparts (Fig 3A).
Lastly for RTD 0-200ms, a one factor ANOVA revealed a main effect of menopause phase/
HRT use (P = 0.001; p2 = 0.220; β = 0.951). Pairwise comparisons revealed pre-menopausal
participants to have 98% (P = 0.001) and 42% (P = 0.046) greater RTD 0-200ms than their
post-menopausal No_HRT and HRT_user counterparts (Fig 3A). There was, however, no sig-
nificant difference in RTD when torque was expressed relative to MVC between groups (See
Fig 3B).
Table 4 illustrates the effect of menopause phase and use/non-use of HRT on mPowerF
assessed during both PF and DF MVC. The PF mean mPowerF across the three groups at rest
(~188±40Hz), and at MVC (~248±26Hz), i.e. ~35% relative increment from rest to MVC,
showed no significant estrogen status effect. There were only trends for mPowerF in the rest-
ing PF to be greater than that of postmenopausal women, whilst at MVC the mPowerF of the
No_HRT became closest to that of the premenopausal women with Used_HRT exhibiting the
lowest values. In the dorsiflexors, the mean mPowerF at rest (~281±47Hz), and at MVC (~251
±24Hz), i.e. ~ -9% relative decrement from rest to MVC, showed no significant estrogen status
effect. Nonetheless mPowerF showed a trend for being highest in the premenopausal women
at rest, during MVC and in terms of relative decrement from rest to MVC in the DF (see
Table 4).
(e) Serum hormone associations against potential indirect muscle fiber type indices and
muscle volume. In Table 5 a series of bivariate correlations were run between serum Estra-
diol levels, T3 levels and the E2:T3 ratio against mPowerF of the gastrocnemius medialis during
PF MVC, mPowerF of the tibialis anterior during DF MVC and the RTD during PF at 0˚ and
muscle quality. Estradiol levels were positively correlated with RTD at 0-50ms (rho = 0.39;
Fig 3. Comparison of participants’ plantar rate of torque development categorized by participants’ menopause phase and use of
hormone replacement therapy. A) Absolute values. Values are means ± SDs. Different from Pre-Menopausal and Post-Menopausal, �
P< 0.05, �� P< 0.01. B. Relative values. Values are RTD relative to each individual’s MVC. Different from Pre-Menopausal and Post-
Menopausal.
https://doi.org/10.1371/journal.pone.0250813.g003
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P = 0.002), 0-100ms (rho = 0.42; P = 0.001), 0-150ms (rho = 0.47; P<0.001), 0-200ms
(rho = 0.48; P<0.001) and muscle quality (rho = 0.32; P = 0.019; Table 5). These positive corre-
lations persisted even after controlling for age (see Table 5). In addition E2:T3 ratio was also
positively correlated with RTD at 0-50ms (rho = 0.37; P = 0.010), 0-100ms (rho = 0.37;
P = 0.010), 0-150ms (rho = 0.36; P = 0.012), 0-200ms (rho = 0.35; P = 0.016). Running correla-
tions for Estradiol after controlling for body fat percentage (a previously identified covariate),
the above-identified positive correlations were strengthened (RTD at 0-50ms (rho = 0.45;
P<0.001), 0-100ms (r = 0.47; P<0.001), 0-150ms (rho = 0.50; P<0.001), 0-200ms (rho = 0.50;
P<0.001). This was mirrored for E2:T3 ratio for RTD at 0-50ms (rho = 0.51; P<0.001), 0-
100ms (rho = 0.46; P = 0.001), 0-150ms (rho = 0.40; P = 0.006) and 0-200ms (rho = 0.38;
P = 0.008).
Finally, there were no significant correlations between Estradiol, T3 or E2:T3 ratio against
GM muscle volume when uncorrected for IMAT. However, when GM muscle volume was
adjusted for IMAT, there was a positive correlation between Estradiol and GM muscle volume
(rho = 0.30; P = 0.027; Table 5). It should be noted that this association between Estradiol and
GM muscle volume adjusted for IMAT, remained when controlling for age in the whole sam-
ple (rho = 0.35; P = 0.009; Table 5), and in the post-menopausal group sample (rho = 0.412;
P = 0.040). However, the association was not present in the pre-menopausal group
(rho = 0.125; P = 0.519).
Discussion
Three key observations in the literature informed this study: (1) previous research links low
thyroid levels with a conversion from fast to slow fiber types [37] (although females with low
thyroid hormones have a higher amount of type II than their male hypothyroidism counter-
parts [20]); (2) low estrogen such as seen in the menopause is synonymous with decreased lean
tissue content [38, 39], lower physical performance [40], and animal work corroborates with
these observation [41, 42]; (3) skeletal muscle is an estrogen-responsive tissue as it contains
receptors for this ligand [43–47]. Based on these observations, it followed that the interaction
Table 5. Bivariate and partial (correcting for age) Spearman correlations between hormone levels against electromyography mean power frequency (pre, during,
change) and rate of torque development.
Plantar Flexion Dorsi Flexion
Mean Power Frequency Rate of Torque
Development
Pre MVC MVC Δ mPowerF Pre MVC MVC Δ mPowerF 0–50 0–100 0–150 0–200 MV (IMAT) MQ (IMAT)
Hormone Levels
Estradiol (E2) pg/ml -0.05 0.24 0.12 0.11 0.05 -0.02 0.39�� 0.42�� 0.47��� 0.48��� 0.30� 0.27�
Tri-iodo-thyronine (T3) ng/dl 0.13 -0.13 0.22 0.19 -0.06 -0.154 0.06 0.09 0.15 0.16 -0.17 0.11
E2:T3 ratio -0.07 0.06 0.05 -0.05 0.06 0.04 0.37� 0.37� 0.36� 0.35� 0.25 0.17
Partial Correlation (age)
Estradiol (E2) pg/ml - - - - - - 0.40�� 0.37�� 0.33� 0.26� 0.35�� 0.11
E2:T3 ratio - - - - - - 0.31� 0.25 0.16 0.09 0.30� -0.22




Abbreviations: mPowerF, mean power frequency; MVC, maximum voluntary contraction; MQ (IMAT), muscle quality corrected for intramuscular adipose tissue; MV
(IMAT), muscle volume corrected for intramuscular adipose tissue.
https://doi.org/10.1371/journal.pone.0250813.t005
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of Estradiol and Tri-iodo-thyronine, even in healthy individuals, would be of clinical interest.
Our study therefore set out to elucidate a few of these point using a cross-sectional design. We
anticipated that (1) Lower levels of estradiol (and/or no HRT history) is linked to decreased
muscle function (decreased isometric MVC, isokinetic strength and muscle quality), (2) Age-
ing is associated with perceptible decrements in T3 levels thereby modulating muscle activa-
tion profile and hence potentially indicating fiber type percentage shift towards a slow
phenotype (resulting in slower rate of torque development–RTD—and lower Mean Power
Frequency–mPowerF-); (3) estradiol to Tri-iodo-thyronine ratio (i.e. E2:T3) is an endocrine
modulator of skeletal muscle phenotype, (4) high body fat in the post-menopausal status alters
muscle EMG profile and RTD (these being two proposed indirect indices of muscle fiber
type), potentially through decreasing the fast-to-slow transition of fiber type in older women.
Estrogen levels affect muscle function
Our data confirms the first hypothesis: Lower levels of estradiol (and/or no HRT history) is
linked to decreased muscle function (decreased isometric MVC, isokinetic strength and mus-
cle quality). Indeed post-menopausal No_HRT women had lower isometric, and isokinetic
torque in both the plantarflexor and dorsiflexor muscle groups, compared to the post-meno-
pausal Used_HRT, themselves having a lesser performance in these muscle strength outcome
measures compared to pre-menopausal women. In parallel and as expected, the grouping
comparison and the correlation between age and Estradiol were statistically significant (rho =
-0.773, p<0.001). These findings are consistent with previous research comparing pre-meno-
pausal to post-menopausal [40], or post-menopausal Used_HRT vs No_HRT [15, 16, 48]. Our
current, results are even more striking when one considers that in the HRT group, therapy had
been ceased 10.6 ± 8.9 years prior to the current study and the levels of estrogen were now
within expected post-menopausal levels [49, 50]. The physiological pathway for the effect of
estrogen on muscle mass and function is proposed to be anti-apoptotic [51] as well as through
IGF-1, a potent stimulator of skeletal muscle growth and regeneration, which is found to be
involved in the estrogen signal transduction pathway [52, 53]. In addition, human skeletal
muscle cell culture work has demonstrated that estradiol and selective estrogen receptor mod-
ulator (SERM) treatments influence estrogen receptor co-regulator gene expression in human
skeletal muscle cells [54]. Our data, which show better physiological reserves in previous HRT
users, would thus suggest that these (cellular and molecular) effects of HRT, are maintained in
the long term, even after cessation of the therapy.
Thyroid hormone levels across the ages, estrogen levels and fiber type
composition
Our second hypothesis was that ageing is associated with decrements in circulating T3 levels
that will be associated with slow-to-fast fiber type transition (resulting in slower rate of torque
development–RTD—and lower Mean Power Frequency–mPowerF-). In our sample of
women, we did not see a systematic decrease in circulating T3 levels with menopause, but we
observed a trend for Used_HRT to have in fact, higher T3 levels than pre-menopausal women.
The grouping comparisons and the correlation between age and T3 revealed no association
(rho = -0.228, p = 0.12) and a post hoc power calculation suggests a sample size of 23 partici-
pants in each group for future work. Notably also the grouping comparisons and the correla-
tion between age and either E2:T3 ratio were statistically significant (rho = -0.630, p<0.001).
These observations are somewhat in agreement with previous research in that whilst thyroid
hormone levels are not necessarily found to alter with healthy ageing in animal models [1], in
humans, however, there is a trend towards decreased T3 with ageing [55]. Some studies
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however show similarly to us, that ageing is not necessarily synonymous with T3 levels
changes. In fact, it would seem that sex here is the factor and in women, free thyroid hormone
levels are not changed with ageing [56].
The physiological pathway for the effect of thyroid on muscle mass and function is pro-
posed, using microarray assays validated through RT-PCR, as being mediated via an upregula-
tion of MDM2 protein which is an E3 ligase [57]. The researchers report that in fact T3
exclusively upregulates MDM2 in type I fibers. What’s more, any attempt at pharmacologically
blocking MDM2 in cultured myocytes leads to a 35% increase in fiber atrophy. This therefore
leads to a magnification of the effect of T3 (increasing its atrophying effects from 12% to 35%).
What is also now understood, is that the dual and yet at times opposing effects of T3 are evi-
dent in skeletal muscle where it not only induces a slow-to-fast transition [21] but also
increases mitochondrial content and myoglobin expression. The net outcome of this mito-
chondrial effect is the facilitation of increased aerobic capacity [58]. At the same time, T3 has
been linked to an increase in protein breakdown [59, 60]. Conversely also, T3 has been linked
to enhanced protein synthesis [61]. It is as yet unclear what conditions prevail for the overall
result of these two opposing forces (catabolic vs anabolic), to ultimately result in a healthy vs a
sarcopenic status. Certainly previous work, including ours, consistently shows a decrease in
muscle tissue content with increased age, both in males [62] and females [24, 34], which would
tend to support the idea that the sarcopenic pathway overrides any anabolic potential in the
effects of T3.
It has been reported that estrogen and thyroid hormone may interact in the regulation of
gene expression, and that thyroid hormone may increase the expression of estrogen receptors
[63–65]. Therefore, our third hypothesis was that, estradiol to Tri-iodo-thyronine ratio (i.e.
E2:T3) is an endocrine modulator of skeletal muscle phenotype. In terms of inferred indices of
fiber type composition, our mPowerF data would tend to support the idea that the DF has a
greater proportion of fast fibers than the PF [66], irrespective of estrogen status. Remarkably,
with comparisons of RTD (at 0-50ms, 0-150ms and 0-200ms regions) in the PF as an indirect
index of this muscle’s fiber type composition, we consistently found a main effect of estrogen
level with differences following a staircase effect with pre-menopausal >>
Used_HRT > No_HRT. These dissimilarities were of high magnitudes, ranging from 42–98%
differences between pairs. As far as how these were associated with hormone levels and/or
ratio, Estradiol and E2:T3 were significantly associated with RTD (in all regions) but T3 on its
own was not singularly associated with any of the outcome variables. mPowerF was not associ-
ated with any hormone levels and/or E2:T3 ratio. Thus our data reach beyond our second
hypothesis. Indeed, they suggest that all things being equal (i.e. only small group differences in
T3 as seen in the present study cohort), the effects of high estrogen levels overshadow those of
T3. Thus overall, estrogen influences a push towards greater RTD which is a potential indica-
tion of greater proportion of type II fiber type. It is timely here to also note that our observa-
tions cannot necessarily be assigned to the effects of Estradiol only. This assertion is on one
main account: the above-described physiological pathway through which each of these hor-
mone is known to affect skeletal muscle. Our data may suggest that the individual variations in
E2:T3 point to a separate importance in this parameter, thereby supporting our third hypothe-
sis. Indeed, we may have expected a loss of association between the hormones and the physio-
logic outcomes, had T3 data only contributed noise in the relationship.
Given that the physiology theorem is that during ramped contractions the motor units are
recruited in an orderly fashion from slow to fast, it could also be surmised that the change in
signal from rest to maximal activity may be yet another valuable indirect indicator of the mus-
cle fiber phenotype. In the plantarflexors, EMG frequency increased by ~35%, whereas in the
dorsiflexors it decreased by ~9% from rest to MVC. We thus infer that whilst in the PF muscle
PLOS ONE Hormonal influence on skeletal muscle
PLOS ONE | https://doi.org/10.1371/journal.pone.0250813 May 5, 2021 15 / 24
efforts occur with an increase in action potentials, the opposite is true for the dorsiflexors.
However, there was no difference in muscle activation strategies between the three estradiol
status groups again bringing into question the usefulness of this EMG measure as an indepen-
dent indirect, non-invasive quantifier of muscle fiber type composition.
The impact of adiposity on estrogen related muscle phenotype
Our fourth and final hypothesis was that high body fat in the post-menopausal status alters
muscle EMG profile, and RTD, both proposed indirect indices of muscle fiber type (potentially
through decreasing the fast-to-slow transition of fiber type) in older women. Total fat mass
was positively correlated with isokinetic DF MVC and PF net MVC 0˚, but negatively associ-
ated with muscle quality, E2:T3, and peak isometric DF MVC. In addition, body fat percentage
was negatively correlated with muscle quality, Estradiol and E2:T3. These associations were in
agreement with our predictions except for the surprising negative correlation between Estra-
diol and body fat percentage (rho = -0.306; P = 0.008) when we would have expected to see
higher Estradiol in the more adipose participants [17]. However, given that HRT supplementa-
tion is previously reported to be associated with better body composition in post-menopausal
women [67], our current results may be suggestive of the body composition improvement
effects of Estradiol to supersede those of high adiposity. Notwithstanding these we observed, as
predicted [24], a negative correlation between body fat percentage against muscle quality
adjusted for IMAT (rho = -0.48; P<0.001). This observation would suggest that as muscle qual-
ity is high, so are Estradiol levels whilst both total body fat mass and relative percent body fat
are low. In other words, estrogen however indirectly, is synonymous with better skeletal mus-
cle phenotype outcome. The distinction of the effects of estrogen were also confirmed in the
use of partial correlations, correcting for age. It is also notable that in the post-menopausal
group, the relationship between estradiol and IMAT corrected muscle volume remained
(rho = 0.412; P = 0.040). Thus, the effect we are describing cannot be said to simply be a factor
of much higher levels of estrogen in the young.
Initially, we anticipated that adiposity may impact on muscle function on several levels,
owing to a number of previous studies that suggest a link between adiposity and neural activa-
tion [24, 68]. Although increased adiposity was associated with decreased muscle quality in the
present study, neither absolute fat mass nor %body fat were found to be associated with any of
the proposed indirect indices of fiber type composition (mPowerF or RTD). This would mean
that at least based on this sample of post-menopausal status segregated women, our fourth
hypothesis which was that high body fat in the post-menopausal status alters muscle EMG pro-
file, and RTD, both proposed indirect indices of muscle fiber type (potentially through
decreasing the fast-to-slow transition of fiber type) in older women, was not supported.
Some of the challenges of this in vivo human work
A potential source of error from our data is linked to the fact that EMG spectra are influenced
by muscle fiber length, temperature, fatigue, as well as body composition [28]. We have now
established that body composition (BMI and Body mass) did not significantly differ between
the 3 groups. Also given the fact that the environment laboratory conditions were standard-
ized, and fatigue was not allowed to build during the test protocol, it leaves only fascicle length
which was not directly controlled. This parameter is affected by the anatomical characteristics
of the individual as well as the stiffness of the tendon/aponeurosis to which the muscle is
attached. Therefore, given the same ankle angle (which we did control for), the length of the
fascicle could still have differed between participants thereby potentially introducing noise in
our data. Moderating this criticism however, is that this is a standard biomechanics assessment
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practice such as seen with previous research which groups tendon properties by estrogen status
[69, 70]; for a review see [71]). Thus, the mean data from the three groups would still be valid
based on similar degree of relative lengthening/shortening of the muscle within each cohort.
Another potential confounding variable is that the effects of T3 are highly muscle depen-
dent. In rats for instance, the effects of the hormone are more marked in the soleus muscle
where it accelerates twitch parameters by up to 57% whilst decreasing the proportion of type I
fibers by up to 77% in both young and old animals [3, 5]. The sensitivity to T3 is less so in the
extensor digitorum longus (EDL) where it accelerates twitch parameters by only up to 24% and
any effect is limited to older animals [1]. To somewhat account for differential sensitivities to
T3, we analyzed two different muscles, PF and DF. Indeed the two are reported as having a dif-
ferent proportion of fiber types, with GM (representative of the PF) having ~50% Type I [72]
vs tibialis anterior (TA; representative of the DF) having ~40% type I [66, 73, 74]. Therefore,
the potential for a low T3-level mediated muscle activation profile, and presumably fiber type
transition towards a slower phenotype, may have had greater scope to be more pronounced in
the ‘faster’ muscle. Data from the TA, a relatively fast muscle, thus tackled this side of the issue
and yet no singular effect of T3 was found. Therefore, we would recommend that future stud-
ies use other, more distinctly fast vs slow muscles, to further elucidate the impact of T3 and
Estradiol, on muscle activation profile and potentially therefore, fiber-type transition.
Lastly, like the majority published research on muscle fiber types, we have expressed our
indirect quantified fiber type as the fractions of fiber numbers. We acknowledge that this is a
simplified binary (fast vs slow) fashion. However fiber types are seldom expressed as the frac-
tions of cross-sectional area [75, 76], possibly owing to the complexity of assuming area and
tissue density when intramuscular collagenous tissue and fatty infiltration can easily confound
any calculation. Where studies have made a point of systematically quantifying exact CSA frac-
tion for fiber types in different muscles [77], they have again confirmed (tough not always e.g.
[6]) the sex dependence. For instance, in the vastus lateralis, it is reported that in terms of rela-
tive CSA, in males IIA> IIX > I, whereas in females I> IIA> IIX [78] thus lending support
to the idea that sex has a major impact on muscle phenotype. At face value, this would suggest
that estrogen has a ‘slowing’ effect on fiber type phenotype. This conclusion is diametrically
opposed to our observation of a ‘speeding’ effect of estrogen on fiber type phenotype. It may
be that either a) in a comparison of females to females, estrogen has a ‘speeding’ effect owing
to the interplay of other hormones, b) based on estrogen receptor numbers and fiber type
prevalence differences between muscle, the effects of estrogen are muscle specific, or c) the dif-
ference in muscle fiber prevalence in men compared to women is linked to one of the plethora
of differences between the two sexes, not necessarily estrogen levels. In short, more work is
required in this area.
Throughout, we have argued the fact that fiber type may be a key modulator of RTD. We
should now also consider that RTD is also affected by tendon properties [79, 80], and that the
RTD in terms of Nm�sec-1 is also, all else being the same, positively related to the maximal
force the muscle can generate. Previous work has shown the impact of tendon on twitch
parameters [79, 80] and plyometric performance [81, 82]. Given this, it may be that the age-
related decrease in RTD that we have attributed to changes in fiber type (consistent with the
animal models), may in fact be an effect of a decrease in tendon stiffness. However, the correla-
tion between estradiol and RTD (even after correction for age), is at odds with the influence of
tendon, where if anything, low estrogen is associated with a stiffer tendon (for a review, see
[71]). Thus, our findings appear consistent with the suggestion that the decrease in RTD data
is reflecting a fast-to-slow fiber type transition during aging, or perhaps an integral skeletal
muscle structure effect [83, 84]. This conclusion corroborates with the work of previous
researcher which suggests direct estrogen effect on myosin-actin coupling [85]. We should
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treat this conclusion with some caution, however, as the RTD normalized to MVC did not
show a significant age-related decline, even though the pattern of change was in the same
direction.
Perhaps one limitation of our study is that we did not assess the dose and duration, nor pos-
sible changes in diet and exercise since menopause, nor possible influences of alcohol con-
sumption and smoking history.
In view of our findings, we recommend that future work uses biopsies to confirm or other-
wise refute our current conclusions regarding the potential fiber type alterations. Though this
may not necessarily have been much of an issue in our case, as we utilized a post-menopausal
sample (hence minimal estrogen levels variations). We also recommend that blood samples
are taken over a course of a few months to confirm the average estrogen (and/or thyroid hor-
mone) levels of each woman.
The data is in this study indicate that the benefits of hormone replacement therapy for mus-
cle function are long lasting even after cessation of said therapy. This may have significant
implications as a limited duration of hormone replacement therapy will diminish the often
reported risks of developing cancer and cardiovascular diseases [86] and hence may increase
the number of women that can safely be prescribed short duration hormone replacement
therapy.
Conclusion
The current study showed a few striking results. First, not only do they confirm the physiologi-
cal advantage of HRT use in terms of physical functions, they demonstrate for the first time
that (assuming similarities of other potential cofounders in the intervening period between
HRT use, cessation and study timelines e.g. habitual lifestyle and health history) these benefits
persist years beyond termination of the therapy. In relation to this, we found that age and body
fat percentages were modulators of estrogen levels and/or ultimately muscle size (especially
when corrected for IMAT) and muscle quality (described as the force normalized to the mus-
cle tissue content). Whether this association is causative remains to be elucidated. One reason
adiposity may have a negative impact on muscle quality may be as it is commonly associated
with low grade inflammation and oxidative stress. Also notable, was our observation that RTD
(but not mPowerF) is associated with Estradiol level and E2:T3 ratio. This may therefore dis-
tinguish RTD as a useful and sensitively maker of estrogen/HRT history effect on skeletal mus-
cle. Whether RTD proposed here as an indirect marker of in vivo muscle fiber composition,
proves to be so, remains to be confirmed. Using this sensitive marker of muscle activation pro-
file (and thus possibly fiber type phenotype), our data additionally suggest that high circulating
estrogen, with unchanging T3 levels, could lead to a marked change in muscle activation pro-
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